Latest Herceptin Stories
EAST HANOVER, N.J., Dec. 12 /PRNewswire/ -- New data from two early clinical studies show that RAD001(R) (everolimus) may overcome resistance to Herceptin(R) (trastuzumab)* in women with HER2-positive metastatic breast cancer.
Monogram Biosciences, Inc. (Nasdaq:MGRM) today announced that additional EGFR/HER assays have been successfully tested in sets of fixed human tumors and are now available for use in drug development programs.
By Liz Szabo Barbara Bradfield has lived to see dramatic changes in breast cancer. When she was diagnosed in 1989, Bradfield's tumor -- which produced an overabundance of a protein called HER2 -- was considered especially deadly.
By EATON, Dan National has been forced to trim its election health pledges due to tough economic times. Policies shed include a costly $40 million insurance rebate for seniors, while questions remain about the fate of funding plans for breast cancer drug Herceptin and Plunketline.
SUCCESSFUL businesswoman Jacqueline Williams was getting ready for a trip to London and taking her normal morning shower before setting off. But that journey never took place. Instead it was the start of a far more harrowing journey that continues to this very day.
By Madeleine Brindley Health Editor A HOSPITAL'S Saturday clinics for women with breast cancer are proving a great success. The innovative clinic at Velindre Cancer Centre has helped to boost capacity at the Cardiff hospital and reduce waiting times for patients.
SOUTH SAN FRANCISCO, Calif., Sept. 23 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. announced today that it has initiated a study, in collaboration with the Dana-Farber Cancer Institute (DFCI), to evaluate Monogram's HERmark(TM) Breast Cancer Assay in metastatic breast cancer.
By Madeleine Brindley PATIENTS are receiving anti-cancer treatments at a special Saturday clinic in a Welsh hospital. Velindre Cancer Centre's weekend clinic has helped to boost capacity at the Cardiff hospital and reduce waiting times for patients.
Invitrogen Corporation, (NASDAQ:IVGN), a provider of essential life science technologies for research, production and diagnostics, has signed an exclusive U.S.
Sarah Cannon Research Institute (SCRI) investigators have found that "smart bomb" therapies are effective in treating breast cancer patients while minimizing side effects. Howard A.
- Growing in low tufty patches.